There is no standard treatment strategy for the third-line and above treatment of advanced
nonsmall cell lung cancer (NSCLC). This study aimed to investigate the effects of anlotinib in …

Background Anlotinib hydrochloride, a novel multi-targeted tyrosine kinase inhibitor (TKI)
was found to exhibit excellent inhibitory efficiency on a variety of receptor tyrosine kinases …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

Background Anlotinib (AL3818) is a novel multi-target angioenesis TKI targeting the VEGFR,
FGFR, PDGFR and c-Kit. In the ALTER0303 trial, Anlotinib as third-line treatment …

Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory
advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched …

Aim: The aim of this randomised, double-blind, placebo-controlled, anlotinb study was to
investigate its efficacy and safety in patients with refractory non-small-cell lung cancer …

Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …

Objective: This study aimed to evaluate the treatment response, survival profiles, prognostic
factors and adverse events of anlotinib in treating advanced non-small cell lung cancer …